Sanofi encounters resistance, lowers price for cancer drug

11/12/2012 | New York Times (tiered subscription model), The

Sanofi announced it would offer a 50% discount to doctors and hospitals on cancer drug Zaltrap after three doctors from Memorial Sloan-Kettering Cancer Center publicized the health system's refusal to prescribe the drug because it was too expensive and no more effective than similar drugs. Medicare reimbursement and patient co-payments will be based on the higher list price in the short term.

View Full Article in:

New York Times (tiered subscription model), The

Published in Briefs: